Asia Pacific Biologics Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Diseases like cancer, rheumatoid arthritis and many more rare diseases for which there were no previous treatment options are treated by using biologics. Medical products originated from living organisms are considered biologic products. Biologics are the new class of protein-based therapeutics that are produced using living organisms, including plants, animals, and microorganisms such as yeast & bacteria.

APAC Biologics Market Size & Growth:

The APAC biologics market was valued to be nearly $XX billion in 2017 and is expected to reach over $XX billion by the end of 2025 with a CAGR of XX% during the APAC biologics market forecasts period 2019-2025. Stringent regulatory process & high capital investment are significantly restraining the market growth. Since biologics drugs are highly complex & required to control & maintain throughout the development & production process. This regulated environment & quality control procedures involve huge capital investment in the initial state of the process. Additionally, biologics are most susceptible to light, heat conditions and need an auspicious environment which is not uniform across the globe. In most emerging markets, biologics has little presence and is one among the promising markets across the globe. Stringent regulatory policies and high-capital investment coupled with limited patient access to reasonable biologics mainly in the developing countries owing to the increasing control and cost for accessing biologics are likely to obstruct the growth of the APAC biologics market. Some of the key drivers that are driving APAC biologics market growth are increasing capital investment from critical players, rising prevalence of chronic diseases, growing demand & higher acceptability for innovative therapies and others. Increase in population & changes in social behaviour is contributing to a steady rise in these common & costly long-term health problems. The middle class is increasing and the urbanisation fast-tracking, people are adopting a more inactive lifestyle. This is increasing obesity rates and causing leading to diabetes on top. Based on the World Health Organization report, chronic disease prevalence is expected to rise by 57% by the year 2020. Emerging markets will be hardest hit as population growth is expected to be most significant in developing nations. Based on the APAC biologics market outlook, the cancer application market size is estimated to proliferate. Since the demand for usage of biologics in cancer treatment. According to APAC biologics market analysis, APAC biologics market size will increase eventually high in the forecast period from 2019-2025.

APAC Biologics Market Share:                                                                                                        

APAC biologics market is segmented by type, products, application and geography. By the product, the market in monoclonal antibodies segment of the biologics market is estimated to grow at the fastest CAGR during the forecast period. These antibodies are made by different immune cells that are all clones of a unique parent cell. These antibodies have a monovalent affinity, and they bind to the same epitope and are used to treat cancer. Regarding application, the market in cancer application of the biologics market is estimated to grow at the fastest CAGR during the forecast period. This growth can be due to increasing demand for biologics in the treatment of cancer to kill cancer cells by body immune system.

Concerning geography, the market is segmented into China, Japan, India, Australia and New Zealand. China is predicted to be a dominant market in the biologics market during 2019 – 2025. China has the significant biologics teams in the world and consequently produces high demand for biologics. India is said to be the fastest growing market regarding biologics. Rising conciseness regarding health & increasing population is boosting the biologics market.

APAC Biologics Market Trends:

• July 2018, New Cell lines produce NIST monoclonal antibody for improved biologic drugs.
• August 2018, while facing authorisations, Samsung ups its investment in biologics.

APAC Biologics Market Research Report:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have a complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
• Regional and APAC diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
• Identifying DROC in the current market and their impact on altering market dynamics.
• Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• Identify the latest developments, market shares and strategies that are employed by the major market players, such as
  • Prana Biotechnologies
  • BTG
  • Merck & Co
  • Novo Nordisk
  • Lonza.
  •  Biomarin
  • Pfizer Inc.
  • TOT Biopharm
  • Allergan Plc.
  • Johnson & Johnson
  • AGC Biologics
  • Astellas Pharma Inc.